SCNX — Scienture Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1382574 ·
Last close
$0.40
Market Cap
$16.25M
52W High
$0.64
52W Low
$0.24
ADV30
428,689
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 56,325 | 53,850 | -3,509,499 | -3,402,264 | 80,661,705 | 3,542,754 | 13,841,265 |
| Dec 2025 | -168,699 | -243,812 | -3,154,363 | -28,120,333 | 84,178,330 | 6,662,008 | 14,057,946 |
| Sep 2025 | 590,050 | 574,621 | -4,361,206 | -3,607,361 | 104,830,290 | 355,692 | 22,160,659 |
| Jun 2025 | 0 | 0 | -5,157,906 | -6,720,573 | 104,294,834 | 15,391 | 26,434,371 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,382,482
Investing CF
$0
Financing CF
$19,733,595
CapEx
—
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-2.34
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-80,551,237
Inventory
$213,408
Receivables
$731,328
ST Investments
—
EBIT TTM
$-39,423,936
Pretax Income TTM
$-43,507,142
Interest Exp TTM
$4,083,206
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$477,676
EBITDA
$-15,273,282
Free Cash Flow
$-815,500
Enterprise Value
$12,800,838
Total Cash
$3,542,754
Total Debt
$10,004
Shares Out
40,630,815
Trailing EPS
$-2.45
Book Value
$1.73
ROE
-56.6%
ROA
-10.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 431,609 | -16,244,792 | -41,512,264 | 84,178,330 | 14,057,946 | — | -13,379,683 |
| Dec 2024 | 136,643 | -14,701,015 | 9,065,798 | 104,853,805 | 25,781,684 | — | -14,265,238 |
| Dec 2023 | 1,363,830 | -4,396,451 | -17,843,574 | 12,532,913 | 11,990,560 | — | -2,225,192 |
| Dec 2022 | 10,250,168 | -2,040,719 | -3,472,099 | 3,710,026 | 3,367,159 | — | -1,564,668 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.21
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HIND | Vyome Holdings, Inc | $16.21M | $2.31 | — |
| LEXX | Lexaria Bioscience Corp. | $16.49M | $0.67 | — |
| CVKD | Cadrenal Therapeutics, Inc. | $15.98M | $5.19 | — |
| MDCX | Medicus Pharma Ltd. | $16.54M | $0.29 | — |
| COCP | Cocrystal Pharma, Inc. | $15.58M | $1.13 | — |
News headlines (Yahoo Finance, 1h cache)
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
2026-05-18 12:38 · Yahoo
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
2026-05-07 12:05 · Yahoo
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
2026-05-06 12:05 · Yahoo
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
2026-04-15 12:05 · Yahoo
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
2026-04-06 12:05 · Yahoo
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
2026-03-30 12:07 · Yahoo
BC-Most Active Stocks
2026-03-11 14:30 · Yahoo
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
2026-03-11 12:05 · Yahoo
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
2026-02-03 13:05 · Yahoo
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
2026-01-14 13:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.